

Proliferative Vitreoretinopathy (PVR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/P9E8DE9B73B7EN.html>

Date: April 2022

Pages: 37

Price: US\$ 2,000.00 (Single User License)

ID: P9E8DE9B73B7EN

Abstracts

Proliferative Vitreoretinopathy (PVR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Vitreoretinopathy (PVR) - Drugs In Development, 2022, provides an overview of the Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline landscape.

Proliferative Vitreoretinopathy (PVR) occurs when a scar forms under or on the retina after retinal detachment, preventing the retina from healing and falling back into place. Risk factors for proliferative vitreoretinopathy include bleeding within the eye, increased inflammation from trauma, high degree myopia (short-sightedness), family history, severe inflammation or complications from diabetes.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Proliferative Vitreoretinopathy (PVR) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy (PVR) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press

releases.

The Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Vitreoretinopathy (PVR) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Proliferative Vitreoretinopathy (PVR) (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Proliferative Vitreoretinopathy (PVR) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Proliferative Vitreoretinopathy (PVR) (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Proliferative Vitreoretinopathy (PVR) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Proliferative Vitreoretinopathy (PVR) (Ophthalmology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Proliferative Vitreoretinopathy (PVR) (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Proliferative Vitreoretinopathy (PVR) - Overview
- Proliferative Vitreoretinopathy (PVR) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Proliferative Vitreoretinopathy (PVR) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Proliferative Vitreoretinopathy (PVR) - Companies Involved in Therapeutics Development
- Aldeyra Therapeutics Inc
- Aptitude Medical Systems Inc
- Focal Point Pharmaceuticals Inc
- Novartis AG
- Panag Pharma Inc
- Ractigen Therapeutics Inc
- Proliferative Vitreoretinopathy (PVR) - Drug Profiles
- Aptamers to Inhibit PDGF for Proliferative Vitreoretinopathy - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- methotrexate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- OM-101 - Drug Profile
- Product Description
- Mechanism Of Action
- onternabez - Drug Profile
- Product Description
- Mechanism Of Action

History of Events

RAG-1C - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit Hdm2 for Proliferative Vitreoretinopathy - Drug Profile

Product Description

Mechanism Of Action

XOMA-089 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Proliferative Vitreoretinopathy (PVR) - Dormant Projects

Proliferative Vitreoretinopathy (PVR) - Product Development Milestones

Featured News & Press Releases

Jan 04, 2022: Aldeyra Therapeutics completes enrollment in part 1 of the phase 3 GUARD trial of ADX-2191 in proliferative vitreoretinopathy

Jul 20, 2021: Aldeyra Therapeutics receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to treat primary vitreoretinal lymphoma

Jun 15, 2020: Aldeyra Therapeutics receives orphan medicinal product designation from the European Commission for ADX-2191 Retinal Disease Program

Apr 15, 2020: Tetra receives FDA Orphan Drug Designation for its ophthalmic clinical program

Feb 24, 2020: Aldeyra Therapeutics provides update on its proliferative vitreoretinopathy drug candidate at 2020 Research & Development Day

Dec 20, 2019: Aldeyra Therapeutics enrolls first patient in Phase III GUARD study

Sep 24, 2019: Aldeyra Therapeutics receives Fast Track Designation for ADX-2191 for the prevention of Proliferative Vitreoretinopathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Proliferative Vitreoretinopathy (PVR), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Proliferative Vitreoretinopathy (PVR) - Pipeline by Aldeyra Therapeutics Inc, 2022

Proliferative Vitreoretinopathy (PVR) - Pipeline by Aptitude Medical Systems Inc, 2022

Proliferative Vitreoretinopathy (PVR) - Pipeline by Focal Point Pharmaceuticals Inc, 2022

Proliferative Vitreoretinopathy (PVR) - Pipeline by Novartis AG, 2022

Proliferative Vitreoretinopathy (PVR) - Pipeline by Panag Pharma Inc, 2022

Proliferative Vitreoretinopathy (PVR) - Pipeline by Ractigen Therapeutics Inc, 2022

Proliferative Vitreoretinopathy (PVR) - Dormant Projects, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Proliferative Vitreoretinopathy (PVR), 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Proliferative Vitreoretinopathy (PVR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/P9E8DE9B73B7EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P9E8DE9B73B7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

